Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

Author:

Matsushita Tadashi1ORCID,Shapiro Amy1,Abraham Aby1,Angchaisuksiri Pantep1,Castaman Giancarlo1,Cepo Katarina1,d’Oiron Roseline1,Frei-Jones Melissa1,Goh Ai-Sim1,Haaning Jesper1,Hald Jacobsen Sanja1,Mahlangu Johnny1,Mathias Mary1,Nogami Keiji1,Skovgaard Rasmussen Josephine1,Stasyshyn Oleksandra1,Tran Huyen1,Vilchevska Kateryna1,Villarreal Martinez Laura1,Windyga Jerzy1,You Chur Woo1,Zozulya Nadezhda1,Zulfikar Bulent1,Jiménez-Yuste Victor1

Affiliation:

1. From the Department of Transfusion Medicine, Nagoya University Hospital, Nagoya (T.M.), and Nara Medical University, Kashiwara (K.N.) — both in Japan; Indiana Hemophilia and Thrombosis Center, Indianapolis (A.S.); the Department of Hematology, Christian Medical College, Vellore, India (A.A.); the Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); the Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University...

Funder

Novo Nordisk

Publisher

Massachusetts Medical Society

Subject

General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies—generational enhancement;Journal of Thrombosis and Haemostasis;2024-02

2. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

3. Hemostasis — A Balancing Act;New England Journal of Medicine;2023-08-31

4. Hemophilia B: Diagnosis and Management;Congenital Bleeding Disorders;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3